Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The stock price of Cytori Therapeutics, Inc. (CYTX - Snapshot Report) gained 2.69% on Thursday, Jun 18, 2013, on the announcement of an agreement with Medistem, Inc. As per the terms of the agreement, Cytori gets the exclusive rights to use Medistem's patent related to stem cell mediated treg activation (US Patent No. 8,241,621).

The licensed patent from Medistem strengthens the protection of Cytori’s autoimmune disease candidates developed on an adipose-derived regenerative cell based platform.

We see this move as a positive for the company and in-line with the company’s strategy. Earlier, in a filing with the US Securities and Exchange Commission (SEC), the company had disclosed that it is looking for additional patents related to its adipose-derived stem and regenerative cells platform.

We believe that strong patent protection is critical for Cytori as several companies including Baxter International Inc. (BAX - Analyst Report) and Shire (SHPG - Analyst Report) are developing cell-based therapies.

Earlier this month, at the JMP Securities Healthcare Conference 2013, Cytori provided an encouraging update on its business. Cytori, which generated revenues of $8.7 million in 2012, expects revenues to jump to $15 million in 2013. Revenues are expected to increase on the back of contract milestone payments from government agencies like the US Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).

Cytori carries a Zacks Rank #2 (Buy). Other stocks, which appear to be favorably placed, include Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%